Neurocrine Not Giving Up On Luvadaxistat Despite Phase II Miss

 
• By Joseph Haas
  
Schizophrenia
Despite disappointing data, Neurocrine thinks its schizophrenia drug could offer cognitive benefit
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D